Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

Elan Turns First Quarter Profit as Tysabri Sales Rise

By Pharmaceutical Processing | April 20, 2011

Elan Corp. said Wednesday it turned a first-quarter profit,
helped by a legal settlement, sales growth for the multiple sclerosis treatment
Tysabri and lower expenses.

Elan earned $68.2 million, or 12 cents per share, in the
three months that ended March 31. That compares with a loss of $6.8 million, or
1 cent per share, in the same quarter last year.

Revenue rose slightly to $313 million.

Analysts surveyed by FactSet forecast, on average, that Elan
would break even on $298.7 million in revenue.

Elan recorded a $78 million gain in the quarter for the
settlement of patent-infringement litigation with Abraxis, which has been
acquired by Celgene Corp.

Elan also said Tysabri sales rose 23 percent in the quarter
to $245.2 million. The drugmaker’s sales remain heavily dependent on Tysabri,
which suppresses the paralyzing effects of MS but carries a risk of a rare
brain-inflaming disease called PML.

Elan jointly markets and sells the drug in partnership with
Biogen Idec Inc. of Cambridge,
Massachusetts.

The company also said selling, general and administrative
expenses fell 10 percent in the quarter. Research and development costs dropped
8 percent.

Elan’s U.S.-traded shares climbed 2 percent, or 17 cents, to
$8.34 in premarket trading.

 

Related Articles Read More >

This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
sherwin-williams-pharma-facility (1)
Sherwin-Williams expands flooring solutions for pharma facilities
PHARMAP 2025: Pharma leaders converge in Berlin for fifth anniversary summit
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE